Conference Program Home
  My Program

All Times EDT

Abstract Details

Activity Number: 12 - Opportunities and Challenges in the Use of External Control Arms in Drug Development
Type: Invited
Date/Time: Sunday, August 7, 2022 : 2:00 PM to 3:50 PM
Sponsor: Biopharmaceutical Section
Abstract #320361
Title: Propensity-Score-Integrated Priors: A Novel Strategy for Leveraging Real-World and Historical Data
Author(s): Junjing Lin* and Margaret Gamalo and Ram Tiwari
Companies: Takeda Pharmaceuticals and Pfizer Inc. and Bristol Myers Squibb
Keywords: real-world evidence; propensity score; Bayesian; external control; data borrowing
Abstract:

As evident by PDUFA VII commitment letter and a potential update of the 21st Century Cures Act, among other documents, the regulatory environment for utilizing real-world evidence to support different stages of drug development has become progressively favorable. With a spectrum of degrees of reliance on real-world data during the trial conduct and analysis, it is imperative to devise methodologies that can rigorously evaluate and incorporate potentially heterogeneous evidence from disparate sources. One key aspect when conducting analysis is to assess both confirmatory and contradictory knowledge during prior construction to avoid cherry-picking advantageous information. To achieve this, propensity scores are employed to minimize selection bias by incorporating supplemental control subjects and accounting for their similarity in terms of pre-treatment characteristics to the subjects in the current trial. In this paper, we consider data borrowing in a single-arm setting. The simulation experiments show that the proposed method reduces prior and data conflict and improves the precision of the of the average treatment effect.


Authors who are presenting talks have a * after their name.

Back to the full JSM 2022 program